Table 2.
Case–control studies evaluating the role of P. acnes in sarcoidosis
| First author/Year (Ref.) | Country | Molecular technique | Sarcoidosis | Controls | OR (95% CI) |
|---|---|---|---|---|---|
| n/N | n/N | ||||
| Robinson, 2013 [24] | USA | PCR for bacterial 16S rDNA | 7/30 | 1/30 | 8.83 (1.01–76.96) |
| Oswald-Richter, 2012 [25] | USA | MALDI-IMS for propionibacterial proteins | 7/15 | 1/4 | 2.63 (0.22–31.35) |
| Yasuhara, 2005 [31] | Japan | PCR for 16S rRNA | 2/6 | 0/6 | 7.22 (0.28–189.19) |
| Gazouli, 2002 [22] | Greece | PCR for 16S rRNA | 0/46 | 0/20 | - |
| Eish, 2002 [35] | Japan | PCR for 16S rRNA | 93/108 | 25/86 | 15.13 (7.39–30.99) |
| Ishige, 1999 [38] | Japan | Quantitative PCR for 16S rRNA | 12/15 | 3/15 | 16 (2.67–95.75) |
| Negi, 2012 [56] | Japan | Immunohistochemical methods (PAG and TIG antibodies) and western blot | 149/196 | 0/79 | 500.43 (30.44–8226.20) |
| Yamada, 2002 [57] | Japan | Quantitative real-time PCR for 16S rRNA | 8/9 | 2/9 | 28 (2.07–379.25) |
| Eishi, 1994 [58] | Japan | PCR for P. acnes DNA | 36/39 | 12/29 | 17 (4.23–68.28) |
| Abe, 1984 [19] | Japan | Isolation of P acnes in culture | 31/40 | 38/180 | 12.87 (5.65–29.34) |
| Hiramatsu, 2003 [59] | Japan | Nested PCR for 16S rRNA | 21/30 | 7/30 | 7.67 (2.42–24.24) |
16S rDNA ribosomal DNA, MALDI-IMS matrix-assisted laser desorption ionization as a mass spectrometry imaging, rRNA ribosomal RNA